{"id":1288,"date":"2026-04-19T17:34:59","date_gmt":"2026-04-19T15:34:59","guid":{"rendered":"https:\/\/epilogy.org\/?p=1288"},"modified":"2026-04-23T00:06:34","modified_gmt":"2026-04-22T22:06:34","slug":"reporting-of-withdrawn-participants-in-randomized-controlled-trials-assessing-targeted-therapies-in-immune-mediated-skin-diseases-a-cross-sectional-study-of-trials-from-systematic-reviews","status":"publish","type":"post","link":"https:\/\/epilogy.org\/fr\/reporting-of-withdrawn-participants-in-randomized-controlled-trials-assessing-targeted-therapies-in-immune-mediated-skin-diseases-a-cross-sectional-study-of-trials-from-systematic-reviews","title":{"rendered":"Qualit\u00e9 du rapport des retraits de participants dans les essais contr\u00f4l\u00e9s randomis\u00e9s \u00e9valuant les th\u00e9rapies cibl\u00e9es dans les maladies cutan\u00e9es \u00e0 m\u00e9diation immunitaire : \u00e9tude transversale \u00e0 partir d\u2019essais issus de revues syst\u00e9matiques"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"1288\" class=\"elementor elementor-1288\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27f909f e-flex e-con-boxed e-con e-parent\" data-id=\"27f909f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c598616 elementor-widget elementor-widget-html\" data-id=\"c598616\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<style>\n.epilogy-accordion{\nbackground:#ffffff;\nborder:1px solid #ead3ee;\nborder-radius:8px;\npadding:20px;\nmargin:24px 0;\nfont-size:13px;\ncolor:#54595F;\nline-height:1.7;\nbox-shadow:0 2px 8px rgba(0,0,0,0.04);\n}\n\n.epilogy-accordion details{\nborder-top:1px solid #eee;\npadding:10px 0;\n}\n\n.epilogy-accordion details:first-of-type{\nborder-top:none;\n}\n\n.epilogy-accordion summary{\ncursor:pointer;\nfont-weight:600;\ncolor:#7C2A86;\nfont-size:13px;\nlist-style:none;\nposition:relative;\npadding-left:18px;\n}\n\n.epilogy-accordion summary::before{\ncontent:\"+\";\nposition:absolute;\nleft:0;\ntop:0;\n}\n\n.epilogy-accordion details[open] summary::before{\ncontent:\"\u2013\";\n}\n\n.epilogy-highlight{\nbackground:#FADFFF;\npadding:14px;\nborder-radius:6px;\nmargin-top:18px;\nfont-size:13px;\nborder-left:4px solid #7C2A86;\n}\n\n.epilogy-highlight h3{\nmargin:0 0 6px 0;\ncolor:#7C2A86;\nfont-size:13px;\n}\n\n.epilogy-highlight a{\nfont-size:12px;\nopacity:0.9;\n}\n\n.epilogy-authors{\nmargin-top:20px;\npadding-top:14px;\nborder-top:1px solid #eee;\n}\n\n.epilogy-authors-title{\nfont-weight:600;\ncolor:#7C2A86;\nmargin-bottom:10px;\n}\n\n.epilogy-authors-grid{\ndisplay:grid;\ngrid-template-columns:repeat(3,1fr);\ngap:10px;\ntext-align:center;\n}\n\n.epilogy-authors-grid img{\nwidth:70px;\nheight:70px;\nobject-fit:cover;\nborder-radius:100%;\ntransition:all .2s ease;\n}\n\n.epilogy-authors-grid span{\ndisplay:block;\nmargin-top:6px;\nfont-size:12px;\n}\n<\/style>\n\n<div class=\"epilogy-accordion\">\n\n<details open>\n<summary>Objectives<\/summary>\n<p>\nTo assess both in publications and trial registries the reporting of reasons of participant withdrawals in randomized controlled trials (RCTs) evaluating targeted therapies for chronic inflammatory skin diseases, to evaluate the discrepancies between these sources and to classify the reported reasons for withdrawal.\n<\/p>\n<\/details>\n\n<details>\n<summary>Study Design and Setting<\/summary>\n<p>\nWe included RCTs published between September 27, 2009, and October 1, 2024, from four systematic reviews assessing the efficacy or safety of targeted therapies in adult patients with plaque psoriasis, hidradenitis suppurativa, atopic dermatitis, or alopecia areata. The main outcome was the proportion of RCTs presenting at least one discrepancy in the number of withdrawn participants (WP) in total and per treatment arm between the published article and the trial registry. For trials reporting the same number of WP in both sources, we also evaluated discrepancies in reasons for withdrawal. We classified the reasons for withdrawal (e.g. inefficacy, adverse events) and the mechanism (e.g. missing at random, missing not at random).\n<\/p>\n<\/details>\n\n<details>\n<summary>Results<\/summary>\n<p>\nAmong the 96\/209 included RCTs reporting WP data for the primary endpoint in both sources, 25 (26%) had discrepancies between sources in total WP number. Then, among the 71 with the same WP number, 5 did not report reasons and 34 report a different number and\/or reasons between sources. Thus, overall, 32\/96 trials (33%) were fully concordant for both WP numbers and reasons. Among the 73 and 59 different reasons reported in publications and trial registries respectively, 70% (51\/73) and 68% (40\/59) were not informative enough to be classified.\n<\/p>\n<\/details>\n\n<details>\n<summary>Conclusion<\/summary>\n<p>\nOur study revealed significant shortcomings in the reporting of participant withdrawals, marked by incomplete data, discrepancies between sources, and a lack of standardized terminology in RCTs evaluating systemic targeted therapies for chronic inflammatory skin diseases.\n<\/p>\n<\/details>\n\n<div class=\"epilogy-authors\">\n<div class=\"epilogy-authors-title\">Epilogy team author<\/div>\n\n<div class=\"epilogy-authors-grid\">\n<div>\n<img decoding=\"async\" src=\"https:\/\/epilogy.org\/wp-content\/uploads\/2026\/03\/Robin_Guelimi.png\">\n<span>Robin Guelimi<\/span>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"epilogy-highlight\">\n<h3>Reporting of withdrawn participants in randomized controlled trials assessing targeted therapies in immune-mediated skin diseases: a cross-sectional study of trials from systematic reviews<\/h3>\n<p style=\"margin:0;\">\n<a href=\"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112273\" target=\"_blank\">\nhttps:\/\/doi.org\/10.1016\/j.jclinepi.2026.112273\n<\/a>\n<\/p>\n<\/div>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8c34503 e-flex e-con-boxed e-con e-parent\" data-id=\"8c34503\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-863e1af elementor-widget elementor-widget-html\" data-id=\"863e1af\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<script>\ndocument.querySelectorAll('.epilogy-accordion details').forEach((detail) => {\n  detail.addEventListener('toggle', function() {\n    if (this.open) {\n      document.querySelectorAll('.epilogy-accordion details').forEach((other) => {\n        if (other !== this) {\n          other.removeAttribute('open');\n        }\n      });\n    }\n  });\n});\n<\/script>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Objectives To assess both in publications and trial registries the reporting of reasons of participant withdrawals in randomized controlled trials (RCTs) evaluating targeted therapies for chronic inflammatory skin diseases, to evaluate the discrepancies between these sources and to classify the reported reasons for withdrawal. Study Design and Setting We included RCTs published between September 27,&hellip;&nbsp;<a href=\"https:\/\/epilogy.org\/fr\/reporting-of-withdrawn-participants-in-randomized-controlled-trials-assessing-targeted-therapies-in-immune-mediated-skin-diseases-a-cross-sectional-study-of-trials-from-systematic-reviews\" rel=\"bookmark\"><span class=\"screen-reader-text\">Qualit\u00e9 du rapport des retraits de participants dans les essais contr\u00f4l\u00e9s randomis\u00e9s \u00e9valuant les th\u00e9rapies cibl\u00e9es dans les maladies cutan\u00e9es \u00e0 m\u00e9diation immunitaire : \u00e9tude transversale \u00e0 partir d\u2019essais issus de revues syst\u00e9matiques<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":1293,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","neve_meta_reading_time":"","footnotes":""},"categories":[1,18,20],"tags":[],"class_list":["post-1288","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-epilogy","category-epinews","category-last-publications"],"_links":{"self":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/1288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/comments?post=1288"}],"version-history":[{"count":8,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/1288\/revisions"}],"predecessor-version":[{"id":1398,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/1288\/revisions\/1398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/media\/1293"}],"wp:attachment":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/media?parent=1288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/categories?post=1288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/tags?post=1288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}